OSD in glaucoma patients

OSD in glaucoma patients
Cheryl Guttman Krader
Cheryl Guttman Krader
Published: Saturday, September 22, 2018
GLAUCOMA is not just an optic neuropathy – it is also an ocular surface disease (OSD), said Florent Aptel MD, PhD. Speaking at the 9th EuCornea Congress, Dr Aptel discussed OSD prevalence among patients with glaucoma and reviewed the etiology, diagnosis and management of OSD. Results of several studies document that OSD is very common in glaucoma patients and show that it is related to the burden of use of medications containing preservatives. For example, one study found that more than half of glaucoma patients using two or three medications containing preservatives had signs or symptoms of OSD. Findings from epidemiologic studies and basic science research establish benzalkonium chloride (BAK) as the primary culprit in medication-related OSD toxicity. “Therefore, it is likely better to avoid glaucoma medications preserved with BAK, especially in patients with OSD as well as in patients who are on multidrug regimens or who will have future filtering surgery,” said Dr Aptel, professor of ophthalmology, University Hospital of Grenoble, Grenoble, France. “Fortunately, there are several preservative-free glaucoma medications available now in both monotherapy and fixed combination options. Results of comparative studies show no differences in the IOP-lowering activity of preservative-containing and preservative-free formulations of the same active ingredient.” Identifying the presence of OSD in patients with glaucoma should begin with a good history. “It is very important to remember that in most patients, the symptoms of OSD precede the physical abnormalities,” Dr Aptel said. Slit-lamp examination and fluorescein staining are generally adequate to assess for signs of OSD.
Tags: cornea, glaucoma, osd
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...